Knight Therapeutics Inc. (KHTRF)
OTCMKTS · Delayed Price · Currency is USD
4.330
+0.085 (2.00%)
Feb 11, 2026, 9:30 AM EST
Knight Therapeutics Revenue
Knight Therapeutics had revenue of 121.55M CAD in the quarter ending September 30, 2025, with 31.74% growth. This brings the company's revenue in the last twelve months to 413.85M, up 18.70% year-over-year. In the year 2024, Knight Therapeutics had annual revenue of 371.30M with 13.13% growth.
Revenue (ttm)
413.85M CAD
Revenue Growth
+18.70%
P/S Ratio
1.45
Revenue / Employee
555.50K CAD
Employees
745
Market Cap
430.65M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 371.30M | 43.11M | 13.13% |
| Dec 31, 2023 | 328.20M | 34.64M | 11.80% |
| Dec 31, 2022 | 293.56M | 50.09M | 20.57% |
| Dec 31, 2021 | 243.48M | 43.96M | 22.03% |
| Dec 31, 2020 | 199.52M | 152.06M | 320.39% |
| Dec 31, 2019 | 47.46M | 34.96M | 279.69% |
| Dec 31, 2018 | 12.50M | 3.87M | 44.78% |
| Dec 31, 2017 | 8.63M | 2.69M | 45.35% |
| Dec 31, 2016 | 5.94M | 4.90M | 472.81% |
| Dec 31, 2015 | 1.04M | 672.00K | 184.11% |
| Dec 31, 2014 | 365.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Knight Therapeutics News
- 2 months ago - Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris - GlobeNewsWire
- 3 months ago - Knight Therapeutics Inc. (GUD:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Knight Therapeutics Reports Third Quarter 2025 Results - GlobeNewsWire
- 3 months ago - Knight Announces Closing of US$100 Million Revolving Credit Facility - GlobeNewsWire
- 3 months ago - Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call - GlobeNewsWire
- 4 months ago - Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada - GlobeNewsWire
- 4 months ago - Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada - GlobeNewsWire
- 4 months ago - Knight Therapeutics Inc. places No. 384 on The Globe and Mail’s seventh annual ranking of Canada’s Top Growing Companies - Financial Post